IST:MEDTR's EV-to-FCF is ranked better than 92.27% of 414
companies
in the Medical Devices & Instruments industry
Industry Median: 23.19
vs IST:MEDTR: 5.69
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's PE Ratio (TTM) for today is calculated as:
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's share price for today is ₺27.96.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺0.150.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS EV-to-FCF Related Terms
MEDITERA TIBBI MALZEMENAYI VE TICARET AS EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS EV-to-FCF Chart
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's EV-to-FCF falls into.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Enterprise Value is ₺2,232 Mil.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺407 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a EV-to-FCF of 5.48 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. This is 39% below median its historical median of 8.94. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #32 out of 414 companies in the Medical Devices & Instruments industry, placing it in the top 7.7%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's EV-to-FCF too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current EV-to-FCF of 5.48 is 39% below median its 10-year median of 8.94. The Medical Devices & Instruments industry median EV-to-FCF is 23.19. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 5.48 is 76.4% below this industry median. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #32 out of 414 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #32 out of 414 companies for EV-to-FCF. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the top 8% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 23.19. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 5.48 is 76.4% below this benchmark. While the company's 10-year median is 8.94 vs. the industry median of 23.19, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.19, based on 414 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current EV-to-FCF of 5.48 is 76.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current EV-to-FCF is 5.48, which is 39% below median its own 10-year median of 8.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺43.77, compared to a current price of ₺27.96 — trading 36.1% below its estimated fair value. The current EV-to-FCF is 5.48, which is 39% below median its 10-year median of 8.94 and 76.4% below the Medical Devices & Instruments industry median of 23.19. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 79/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current EV-to-FCF is 5.48 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺27.96 is trading 36.1% below its estimated GF Value™ of ₺43.77.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
EV-to-FCF: 5.48 (39% below median its 10-year median of 8.94)
GF Value™: ₺43.77 vs. price of ₺27.96 (36.1% below fair value)
Industry Position: 76.4% below the Medical Devices & Instruments median (#32 of 414)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Business Description
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
79GF Score
Get the complete analysis for IST:MEDTR
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
